ReviewFrontiers in veterinary science2026
Ivermectin in veterinary medicine: a narrative review of antiparasitic efficacy, resistance evolution, antiviral evidence, and One Health implications.
Review in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ivermectin is a common macrocyclic lactone that is proven to be active against a wide range of parasites in veterinary medicine. This article presents a narrative review that combines evidence on the antiparasitic effects of ivermectin, its therapeutic use in animals, the development of resistance, preliminary antiviral studies, and ecological consequences within a One Health framework. A comprehensive literature search was conducted through PubMed, Scopus, Web of Science, and Google Scholar for literature published between 1980 and 2025, and the evidence was synthesized qualitatively. Its main antiparasitic effect is mediated via glutamate-gated chloride channels in invertebrates, resulting in neuromuscular paralysis. Clinical benefit of established antiparasitic indications is best evidenced, but the results of treatment depend on the species of the parasite, the host species, the formulation, dosing conditions, and the baseline resistance condition. The antiviral effects reported are mostly exploratory, with most being the results of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.